Jason Scott Slakter - Net Worth and Insider Trading

Jason Scott Slakter Net Worth

The estimated net worth of Jason Scott Slakter is at least $42,782 dollars as of 2024-05-14. Jason Scott Slakter is the CEO of NeuBase Therapeutics Inc and owns about 113,181 shares of NeuBase Therapeutics Inc (NBSE) stock worth over $42,782. Details can be seen in Jason Scott Slakter's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Jason Scott Slakter has not made any transactions after 2017-04-10 and currently still holds the listed stock(s).

Transaction Summary of Jason Scott Slakter

To

Jason Scott Slakter Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jason Scott Slakter owns 1 companies in total, including NeuBase Therapeutics Inc (NBSE) .

Click here to see the complete history of Jason Scott Slakter’s form 4 insider trades.

Insider Ownership Summary of Jason Scott Slakter

Ticker Comapny Transaction Date Type of Owner
NBSE NeuBase Therapeutics Inc 2017-04-10 director

Jason Scott Slakter Latest Holdings Summary

Jason Scott Slakter currently owns a total of 1 stock. Jason Scott Slakter owns 113,181 shares of NeuBase Therapeutics Inc (NBSE) as of April 10, 2017, with a value of $42,782.

Latest Holdings of Jason Scott Slakter

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
NBSE NeuBase Therapeutics Inc 2017-04-10 113,181 0.38 42,782

Holding Weightings of Jason Scott Slakter


Jason Scott Slakter Form 4 Trading Tracker

According to the SEC Form 4 filings, Jason Scott Slakter has made a total of 0 transactions in NeuBase Therapeutics Inc (NBSE) over the past 5 years. The most-recent trade in NeuBase Therapeutics Inc is the acquisition of 7,143 shares on April 10, 2017, which cost Jason Scott Slakter around $100,001.

Insider Trading History of Jason Scott Slakter

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jason Scott Slakter Trading Performance

GuruFocus tracks the stock performance after each of Jason Scott Slakter's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Scott Slakter is -6.52%. GuruFocus also compares Jason Scott Slakter's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Scott Slakter within 3 months outperforms 1 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jason Scott Slakter's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jason Scott Slakter

Average Return

Average return per transaction

Outperforming Transactions

0 out of 10 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 1.22
Relative Return to S&P 500(%) 0.94

Jason Scott Slakter Ownership Network

Ownership Network List of Jason Scott Slakter

No Data

Ownership Network Relation of Jason Scott Slakter


Jason Scott Slakter Owned Company Details

What does NeuBase Therapeutics Inc do?

Who are the key executives at NeuBase Therapeutics Inc?

Jason Scott Slakter is the director of NeuBase Therapeutics Inc. Other key executives at NeuBase Therapeutics Inc include 10 percent owner Symetryx Corp , 10 percent owner Barry Shiff , and 10 percent owner Aleta Shiff .

NeuBase Therapeutics Inc (NBSE) Insider Trades Summary

Over the past 18 months, Jason Scott Slakter made no insider transaction in NeuBase Therapeutics Inc (NBSE). Other recent insider transactions involving NeuBase Therapeutics Inc (NBSE) include a net sale of 428,444 shares made by Symetryx Corp ,

In summary, during the past 3 months, insiders sold 0 shares of NeuBase Therapeutics Inc (NBSE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 489,520 shares of NeuBase Therapeutics Inc (NBSE) were sold and 61,076 shares were bought by its insiders, resulting in a net sale of 428,444 shares.

NeuBase Therapeutics Inc (NBSE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

NeuBase Therapeutics Inc Insider Transactions

No Available Data

Jason Scott Slakter Mailing Address

Above is the net worth, insider trading, and ownership report for Jason Scott Slakter. You might contact Jason Scott Slakter via mailing address: 57 Meadow Woods Road, Great Neck Ny 11020.

Discussions on Jason Scott Slakter

No discussions yet.